https://pittplusme.org/study/2471
Metered Dose Inhaler - Healthy Volunteer
STUDY BASICS
Are you a healthy volunteer between 18 and 60 years old? You may be able to participate in a research study to test an inhaler that uses a new kind of propellant. We want to understand whether the kind of propellant used in an inhaler affects how people clear mucus from their lungs.
STUDY PURPOSE
Inhalers are medical devices that make a spray that people with lung diseases can inhale to help their breathing. A propellant in the inhaler pushes the medicine out and makes the spray. We are doing this study to compare a new propellant for inhalers (hydrofluoroolefin) to the kind of used in most inhalers now (hydrofluoroalkane). We specifically want to know if the kind of propellant used in the inhaler affects how well mucus clears from the lungs. We will ask you to use each inhaler for a week and measure your mucus clearance using a special kind of imaging test (like an x-ray) before and after you use the inhaler.
COULD THIS STUDY BE RIGHT FOR YOU?
- 18 to 60 years old
- Non-smoker/non-vaper
- Not pregnant or nursing
- No history of lung disease
- Not using medications regularly
WHAT PARTICIPANTS CAN EXPECT
You will be in the study for approximately eight weeks. There are 5 site visits of approximately 2 to 6 hours each. You will do breathing tests and have blood drawn and perform 4 lung scans. You will be asked to perform a drug screening. Compensation will be provided.
IRB: SSU00210197
- AstraZeneca AB - D5985C00006, A Randomized, Double-blind, Two-way Crossover Study to Assess the Effect of Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) on Mucociliary Clearance Compared with Hydrofluoroalkane (HFA) Propellant MDI in Healthy Participants (Pro00068187)
MEET THE RESEARCHER
Timothy Corcoran ,
Timothy E. Corcoran, PhD is an Associate Professor of Medicine and Bioengineering. Dr. Corcoran’s primary research interests include aerosol drug delivery and aerosol-based nuclear imaging of the lung. He has been involved in the development of inhaled medications for lung transplant recipients and cystic fibrosis patients and the development special techniques for improving inhaled drug delivery such as the use of low-density gases and surfactants to improve drug distribution in the lungs. Dr. Corcoran had developed imaging techniques for quantifying pulmonary physiology including measurements of mucociliary clearance and liquid absorption in the airways. These techniques have been tested in a series of clinical studies involving adult and pediatric patients and will be used to screen new medications for treating lung diseases such as cystic fibrosis, asthma, and COPD.